NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30573629.
- Also identified by DOI 10.1126/science.aas9090 and PMC identifier 6711172.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Molecularly targeted therapies aim to obstruct cell autonomous programs required for tumor growth. We show that mitogen-activated protein kinase (MAPK) and cyclin-dependent kinase 4/6 inhibitors act in combination to suppress the proliferation of KRAS-mutant lung cancer cells while simultaneously provoking a natural killer (NK) cell surveillance program leading to tumor cell death. The drug combination, but neither agent alone, promotes retinoblastoma (RB) protein-mediated cellular senescence and activation of the immunomodulatory senescence-associated secretory phenotype (SASP). SASP components tumor necrosis factor-α and intercellular adhesion molecule-1 are required for NK cell surveillance of drug-treated tumor cells, which contributes to tumor regressions and prolonged survival in a KRAS-mutant lung cancer mouse model. Therefore, molecularly targeted agents capable of inducing senescence can produce tumor control through non-cell autonomous mechanisms involving NK cell surveillance.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Cyclin-Dependent Kinase 4
- Cyclin-Dependent Kinase 6
- Cytostatic Agents
- Cytotoxicity, Immunologic
- Immunologic Surveillance
- Killer Cells, Natural
- Lung Neoplasms